主页 > 国内 >

中学生计算机在线

中国学者发现新的抗HIV蛋白药物研发HIV蛋白新浪技术

    It can inhibit early virus gene synthesis and late infection ability, and help to develop new anti-AIDS drugs. Beijing News (reporter Xu Wen) has a new target for anti-AIDS drug research and development. Recently, Chinese scholars have discovered a new anti-HIV protein PSGL-1 in human cells. It has multiple antiviral functions, inhibits HIV DNA replication and inhibits a new round of infection of new virus particles. This is expected to become a new direction of anti-HIV drug development. In an interview with the Beijing News, the head of the research group said that the research team was screening small molecules based on the research results. If progress is successful, three to five years will lead to the pre-clinical trial stage. The new anti-HIV protein "one in a million" was discovered by Tan Xu, School of Pharmacy, Tsinghua University, and Zhou Feng, Fudan University, and Wu Yuntao, George Mason University. Tan Xu told reporters that this study for the first time found and confirmed that PSGL-1 is an anti-HIV protein with a new antiviral mechanism. It has multiple antiviral functions, including inhibiting HIV DNA replication and inhibiting a new round of infection of new virus particles. By comparing the levels of cellular proteins in human immune cells before and after HIV infection, the team found that nearly 1,000 of the 14,000 proteins identified had significant changes. Then, by comparing with other databases, PSGL-1, a protein with unknown function in HIV infection, was screened out. In this latest study, researchers have found that high levels of PSGL-1 can inhibit DNA synthesis during the prophase of viral infection. More importantly, when the newly generated virus is released, PSGL-1 can be encapsulated in the released virus, thus further and more strongly inhibiting a new round of virus infection. It is not the first time that antiviral proteins have been discovered. In the past decade, scientists have discovered several antiviral proteins in virus host cells. Under certain conditions, these proteins can inhibit virus replication at all stages of the HIV life cycle. But "Tao is one foot tall, demon is one foot tall". HIV has also evolved a corresponding antagonistic mechanism, almost every protein can be "targeted" by an assistant protein of HIV, for example, APOBEC3G will be degraded by Vif protein. By degrading these proteins, HIV skillfully avoids the natural immune system and eventually successfully infects cells and replicates. PSGL-1 is no exception. "Cunning" HIV, through its accessory protein Vpu, binds to PSGL-1 and promotes the degradation of PSGL-1, thus escaping the antiviral function of PSGL-1 and making PSGL-1 "exhaustive in military work". The findings of this study provide a new target for AIDS drug research and development. Tan Xu revealed that the research team is currently screening small molecular drugs, "If a small molecular compound can inhibit HIV protein, so that it can not destroy the antiviral protein, we can save the antiviral protein, let it play an antiviral role again, so it is possible to find a very effective new type of anti-AIDS drugs." Tan Xu, a research fellow at the School of Pharmacy, Tsinghua University, who is in charge of the dialogue group, needs at least seven to eight years [to talk about new discoveries] to inhibit the next round of infection of new viruses: What is the research process? Tan Xu: The research started after returning to China in 2014 and lasted five years. This discovery provides a new target for AIDS drug research and development. It can also help us understand how the human immune system interferes with the virus and how the defense mechanism works. It can also serve as a reference for the research of other viruses. Antiviral proteins are so powerful that HIV can't bypass them. It has to evolve a mechanism of destruction and eradicate them, otherwise the virus can't replicate and survive. If a small molecule compound can inhibit the HIV protein and make it unable to destroy the antiviral protein, it can rescue the antiviral protein and make it play its antiviral role again, so it is possible to find a very effective new anti-AIDS drug. Following the publication of the research results, we need to screen small molecular drugs, hoping to find them and apply for patents, and then further transform them. Quickly, three or five years to the pre-clinical stage, until human trials at least seven or eight years. New Beijing News: What's the difference between the new findings and "cocktail therapy"? Tan Xu: It has a good complementary effect, but the mechanism is completely different. "Cocktail therapy" drugs are mostly acting on the virus itself, HIV is prone to mutation, drug resistance. Drugs targeting anti-HIV proteins act on host cell proteins, that is, human cells themselves. If developed successfully, drug resistance may not be easy to produce. Beijing News: Scientists have also found other types of anti-HIV proteins? Tan Xu:是的,

    

当前文章:http://www.beikexiyi.com/vgf3m5/43808-367415-71284.html

发布时间:04:15:14

366行业资讯网  

{相关文章}

中信证券:不应过于乐观解读3000亿清单中部分商品暂缓加征关税

    

中信证券指出,美国官方宣布对华3000亿加税清单中部分商品暂缓加征关税至12月15日,其余部分从9月1日起加征10%关税。根据3000亿加税清单估算,暂缓商品规模约占3000亿清单商品的比例为57%。我们认为,美方对部分商品暂缓加征关税主要是因为郑州轻工业学院是几本_366行业资讯网这部分商品对中国市场的依赖度高(大多在70%~90%以上),加征关税对美国消费者影响较大,而其余部分从9月1日服务行业适合男性么_366行业资讯网起加征10%关税也有悖美方在日本大阪G20中美元首峰会上所作的承诺,中美贸易摩擦的根本性好转仍有待于美方改变极限施压的错误做法。从市场策略角度看,相比之前宣布3000亿清单全部加征关税,部分商品暂缓加征关税的情形“优于”市场预期,因此有助于夯实市场的底部,但并非中美贸易摩擦根本性的好转,而A股中期互联网金融业态有哪些_366行业资讯网做多窗口再次打开,还需要耐心等待基本五星级酒店品牌_366行业资讯网面和流动性的空间打开。

    

    

    

    

(责任编辑: HN666)

    

  旅行社责任险内容_366行业资讯网  

    

    

 &nb第一台计算机图片_366行业资讯网sp;  

【责任编辑:admin】
最新文章
热门文章